Avinoam Ophir*

Professor, Ophthalmology Clinic, 48 Sokolov, Ramat-Hasharon, Israel

*Corresponding Author: Avinoam Ophir, Professor, Ophthalmology Clinic, 48 Sokolov, Ramat-Hasharon, Israel.

Received: March 14, 2022; Published: April 13, 2022

Abbreviations

FDA: Food and Drug Administration; DME: Diabetic Macular Edema; DDME: Diffuse DME; nAMD: Wet age-related Macular Degeneration; VA: Visual Acuity; BCVA: Best-corrected Visual Acuity; mGLP: Modified Grid Laser Photocoagulation; OCT: Optical Coherence Tomography; SD-OCT: Spectral-domain OCT; PPV: Pars Plana Vitrectomy; VFT: Vitreofoveal Traction; ERM: Epiretinal Membrane; -VEGF: -Vascular Endothelial Growth Factor; DRCR.net: Diabetic Retinopathy Clinical Research Network; CMT: Central Macular Thickness; PVD: Posterior Vitreous Detachment.

Keywords: Diabetic Macular Edema; Extrafoveal traction; Vasogenic Macular Edema; Dry macular Edema; 3D-OCT; Pars Plana Vitrectomy; Grid Laser Photocoagulation; Focal Laser Photocoagulation; Anti-VEGF; Biosimilar; Ranibizumab; Aflibercept; Bevacizumab; Byooviz

References

1. https://www.fda.gov/news events/press announcements/fda approves first- biosimilar treat macular degeneration disease and other eye conditions (2021).
2. Kapur M., et al. “Future of anti‑VEGF: biosimilars and biobetters”. International Journal of Retina and Vitreous 8 (2022): 2.
3. Woo SJ., et al. “Efficacy and safety of a proposed ranibizumab. Biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial”. Jama Ophthalmology 139 (2021): 68-76.
4. Sadda SR., et al. “Relationship between duration and extent of edema and visual acuity outcome with ranibizumab in diabetic macular edema: A post hoc analysis of Protocol I data”. Eye 34 (2020): 480-490.
5. Sakamoto A., et al. “Association between foveal photoreceptor status and visual acuity after resolution of diabetic macular edema by pars plana vitrectomy”. Graefe’s Archive for Clinical and Experimental Ophthalmology 247 (2009): 1325-1330.
6. Cennamo G., et al. “Evaluation of vessel density in disorganization of retinal inner layers after resolved diabetic macular edema using optical coherence tomography”. PLoS One 1 (2021): 0244789.
7. Early Treatment Diabetic Retinopathy Study Research Group. “Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report No. 19”. Archives Ophthalmology 113 (1995): 1144-1155.
8. Schmidt-Erfurth U., et al. “Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)”. Ophthalmologica 237 (2017): 185-222.
9. Bonnin S., et al. “Vitrectomy with internal limiting membrane peeling for tractional and nontractional diabetic macular edema. Long-term results of a comparative study”. Retina 35 (2015): 921-928.
10. Flaxel CJ., et al. “Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research network”. Retina 30 (2010): 1488-1495.
11. Ivastinovic D., et al. “Vitrectomy for diabetic macular edema and the relevance of external limiting membrane”. BMC Ophthalmology 21 (2021): 334.
12. Lee CM and Olk RJ. “Modified grid laser photocoagulation for diffuse DME. Long-term visual results”. Ophthalmology 98 (1991): 1594-1602.
13. Arevalo JF., et al. “Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema”. Retina 33 (2013): 403-413.
14. Elman MJ., et al. “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema”. Ophthalmology 117 (2010): 1064-1077.
15. Mitchell P., et al. “The RESTORE Study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema”. Ophthalmology 118 (2011): 615-625.
16. Brown DM., et al. “Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122 (2015): 2044-2052.
17. Wells JA., et al. “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema”. New England Journal of Medicine 372 (2015): 1193-1203.
18. Wells JA., et al. “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial”. Ophthalmology 123 (2016): 1351-1359.
19. Blinder KJ., et al. “Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)”. Clinical Ophthalmology 11 (2017): 393-401.
20. Uji A., et al. “Influence of vitrectomy surgery on the integrity of outer retinal layers in diabetic macular edema”. Retina 38 (2018): 163-172.
21. Miyamoto N., et al. “Restoration of photoreceptor outer segments up to 24 months after pars plana vitrectomy in patients with diabetic macular edema”. Ophthalmology Retina (2017): 1-6.
22. Ophir A., et al. “Extrafoveal vitreous traction associated with diabetic diffuse macular edema”. Eye (Lond) 24 (2010): 347-353.
23. Ophir A., et al. “Vitreous traction and epiretinal membranes in diabetic macular edema using spectraldomain optical coherence tomography”. Eye (Lond) 24 (2010): 1545-1553.
24. Ophir A. “Full-field 3-D optical coherence tomography imaging and treatment decision in diffuse diabetic macular edema”. Investigative Ophthalmology and Visual Science 55 (2014): 3052-3053.
25. Adhi M., et al. “Three-dimensional enhanced imaging of vitreoretinal interface in diabetic retinopathy using swept-source optical coherence tomography”. American Journal of Ophthalmology 162 (2016): 140-149.
26. Fatima N., et al. “Frequency of vitreomacular traction in diabetic macular edema on optical coherence tomography”. Pakistan Armed Forces Medical Journal 67 (2017): 47-50.
27. La Haij EC., et al. “Vitrectomy results in diabetic macular edema without evident vitreomacular traction”. Graefe's Archive for Clinical and Experimental Ophthalmology 239 (2001): 264-270.
28. Yanyali A., et al. “Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema”. American Journal of Ophthalmology 139 (2005): 795-801.
29. Iglicki M., et al. “Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study”. PloS One 7 (2018).
30. Michalewska Z., et al. “Vitrectomy in the management of diabetic macular edema in treatment-naïve patients”. Canadian Journal of Ophthalmology 53 (2018): 402-407.
31. Karatas M., et al. “Diabetic vitreopapillary traction and macular edema”. Eye (Lond) 19 (2005): 676-682.
32. Sebag J. “Vitreoschisis”. Graefes Archives Clinical Experimental Ophthalmology 246 (2008): 329-332.
33. Ophir A and Martinez MR. “Epiretinal membranes and incomplete posterior vitreous detachment in diabetic macular edema, detected by spectral-domain optical coherence tomography”. Investigative Ophthalmology Visual Sciences 52 (2011): 6414-6420.
34. Landers MB III., et al. “Early vitrectomy for DME: Does it have a role?” Retinal Physician 10 (2013): 46-53.
35. Adelman R., et al. “Strategy for the Management of Diabetic Macular Edema: The European Vitreo-Retinal Society Macular Edema Study”. BioMed Research International (2015).
36. Hagenau F., et al. “Vitrectomy for diabetic macular edema: Optical coherence tomography criteria and pathology of the vitreomacular interface”. American Journal of Ophthalmology 200 (2019): 34-46.
37. Stefansson E., et al. “Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy”. Transactions American Ophthalmological Society 79 (1981): 307-333.
38. Kogo J., et al. “Foveal microstructure analysis in eyes with diabetic macular edema treated with vitrectomy”. Advances in Therapy 34 (2017): 2139-2149.
39. Vikas SJ., et al. “Comparison of anatomical and functional outcomes of vitrectomy with internal limiting membrane peeling in recalcitrant diabetic macular edema with and without traction in Indian patients”. Indian Journal Ophthalmology 69 (2021): 3297-3301.
40. Hwang S., et al. “Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema”. Scientific Reports 11 (2021): 1292.
41. Berrocal MH., et al. “Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature”. Current Opinion Ophthalmology 32 (2021): 203-208.
42. Ophir A., et al. “Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema”. International Journal of Ophthalmology 6 (2013): 836-843.
43. Ophir A. “Achieving durable dry macula in diffuse diabetic macular edema: A meta-analysis". Acta Scientific Ophthalmology 3 (2021): 91-104.
44. Shanmugam MP., et al. “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial”. Ophthalmology 124 (2017): e5.
45. Wells JA., et al. Reply: “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial”. Ophthalmology 124 (2017): e5-6.
46. Kulikov AN., et al. "Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: An optical coherence tomography study". Clinical Ophthalmology (Auckland, NZ) 11 (2017): 1995-2002.
47. Dugel PU., et al. "Association between early anatomic response to anti-vascular endothelial growth factor therapy and longterm outcome in diabetic macular edema". Retina 39 (2019): 88-90.
48. Egan C., et al. “The United Kingdom diabetic retinopathy electronic medical record users group, Report 1: Baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular edema”. British Journal of Ophthalmology 101 (2017): 75-78.
49. Glassman AR., et al. “Five-Year Outcomes after initial Aflibercept, Bevacizumab, or Ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)”. Ophthalmology 127 (2020): 1201-1210.
50. Ciulla TA., et al. “Real-world outcomes of anti- vascular endothelial growth factor therapy in diabetic macular edema in the United States”. Ophthalmology Retina 2 (2018): 1179-1187.

Citation

Citation: Avinoam Ophir. “Are Anti-vascular Endothelial Growth Factor Biosimilars Applicable for Treating Diabetic Macular Edema?".Acta Scientific Ophthalmology 5.5 (2022): 22-26.

Copyright

Copyright: © 2022 Avinoam Ophir. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.